'Unprecedented' tobacco industry campaign undermined report on second-hand smoke and cancer, researchers said

April 05, 2000

A ten-year study conducted by the International Agency for Research in Cancer (IARC) examining the links between second-hand smoke and cancer was subverted by an unprecedented misinformation campaign coordinated by the tobacco industry and resulting in misleading media reports of the European scientific study even before it was published.

These are the findings of two UC San Francisco scholars whose analysis of the fierce tobacco industry information campaign is published in the April 8 issue of the medical journal Lancet. Authors are Elisa K. Ong, BA, and Stanton Glantz, PhD, both researchers at the Institute for Health Policy Studies in UCSF's Department of Medicine.

"The extent of tobacco industry money and effort spent to discredit a single study is unprecedented," said Glantz, professor of medicine at UCSF and long-time scholar and critic of tobacco industry strategies. Ong is a medical student at Stanford University.

The reason the industry was so concerned about the paper, he suggests, is that while scientific reports on second-hand smoke had already stimulated legislation on clean indoor air in the U.S., European countries have been slower to change.

"Tobacco industry strategists were apparently trying to head off the possibility of sentiment growing for similar restrictions in their European markets, so they hit this report with all they had," Glantz says. "There seems to be little regard for the truth in the information they tried to spread."

In their paper, Ong and Glantz describe how the tobacco industry worked to undermine the conclusions and potential impact of the largest European study of passive smoking, conducted by IARC, the research arm of the World Health Organization (WHO).

Fearing that the IARC study (and a possible IARC monograph summarizing all scientific evidence linking second-hand smoke to disease) would lead to increased European smoking restrictions, the Phillip Morris tobacco company spearheaded an inter-industry, three-pronged strategy in the mid 1990s to subvert IARC's work, write Glantz and Ong. The scientific strategy attempted to undercut IARC's research and to develop industry-directed research to counter the anticipated findings; the communications strategy planned to shape opinion by manipulating the media and the public; the government strategy sought to prevent increased smoking restrictions.

The IARC scientific study cost roughly $2 million over ten years; Philip Morris planned to spend $2 million in one year alone and up to $4 million on research, the authors report. Part of Philip Morris' strategy was to use consultants sympathetic to the tobacco industry who were asked to find out more about the IARC report, and did not always disclose their industry links while seeking information from IARC investigators. The documents and interviews suggest that the tobacco industry continues to conduct a sophisticated campaign against conclusions that second-hand smoke causes lung cancer and other diseases, "subverting normal scientific processes," the authors conclude.

The IARC study demonstrated a 16% increase in risk in lung cancer to nonsmokers from second-hand smoke, a result consistent with earlier studies. Although the results were clear and comparable to those found by others, the number of people in the study was too small to reach statistical significance (at the 95 percent level).

As Ong and Glantz document, the tobacco industry exploited the degree of statistical uncertainty by providing selected newspapers with the misinformation that the study had demonstrated "no risk" of cancer from second-hand smoking - clearly not the study's finding. These incorrect conclusions were published in the British press before the scientific study was published, and as an official British report reviewing second-hand smoke's health effects was released.

To understand the tobacco industry's strategy regarding the IARC study, Ong and Glantz interviewed IARC investigators and analyzed tobacco industry documents among 32 million pages released in 1998 as part of the settlement of the legal case, State of Minnesota and Blue Cross/Blue Shield of Minnesota vs Phillip Morris, Inc. The documents are archived in Minneapolis.
-end-
The study by Ong and Glantz was supported by a grant from the National Cancer Institute.

University of California - San Francisco

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.